Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?

Hims & Hers Health (NYSE: HIMS) demonstrated once again why it's one of the most interesting growth stocks outside of the tech sector when it reported strong Q3 results. While the stock has been volatile this year, it is trading up more than 80% in 2025, as of this writing.Let's take a closer look at the most recent earnings results for this telehealth company to see if now is a good time to buy the stock.Hims & Hers delivered yet another strong quarter of revenue growth in Q3, with sales climbing 49% year over year to $599 million. That was above the high end of its $570 million to $590 million guidance, and above the $582 million analyst consensus, as compiled by Factset. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool